Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PBH logo PBH
Upturn stock ratingUpturn stock rating
PBH logo

Prestige Brand Holdings Inc (PBH)

Upturn stock ratingUpturn stock rating
$86
Delayed price
Profit since last BUY-1.35%
upturn advisory
Consider higher Upturn Star rating
BUY since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: PBH (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 10.1%
Avg. Invested days 38
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.26B USD
Price to earnings Ratio 20.19
1Y Target Price 89.14
Price to earnings Ratio 20.19
1Y Target Price 89.14
Volume (30-day avg) 319228
Beta 0.51
52 Weeks Range 62.35 - 88.36
Updated Date 02/15/2025
52 Weeks Range 62.35 - 88.36
Updated Date 02/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 4.26

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-02-06
When Before Market
Estimate 1.2
Actual 1.22

Profitability

Profit Margin 19.13%
Operating Margin (TTM) 31.68%

Management Effectiveness

Return on Assets (TTM) 6.19%
Return on Equity (TTM) 12.63%

Valuation

Trailing PE 20.19
Forward PE 18.12
Enterprise Value 5236512154
Price to Sales(TTM) 3.81
Enterprise Value 5236512154
Price to Sales(TTM) 3.81
Enterprise Value to Revenue 4.68
Enterprise Value to EBITDA 14.53
Shares Outstanding 49537800
Shares Floating 49032553
Shares Outstanding 49537800
Shares Floating 49032553
Percent Insiders 2.4
Percent Institutions 108.54

AI Summary

Prestige Brands Holdings, Inc.: A Comprehensive Overview

Company Profile

History and Background

Prestige Brands Holdings, Inc. (PBH) is a leading marketer and distributor of over-the-counter (OTC) healthcare and household products in the United States and Canada. Its history dates back to 1948 with the founding of DeWitt International Corporation, now one of its subsidiaries. Over the years, PBH evolved through acquisitions and organic growth, becoming a publicly traded company on the Nasdaq in 2011.

Core Business Areas

PBH focuses on four core business areas:

  • OTC Healthcare: Comprises various internal analgesics, cold and allergy remedies, digestive aids, and cough and sore throat remedies. Popular brands include Chloraseptic, Dramamine, Clear Eyes, Theobromine, and PediaCare.
  • Household: Includes cleaning products and pest control items. Popular brands include Comet, Enoz, and Duck Fresh Discs.
  • Specialty: Includes personal care, sun care, and nutritional supplement products. Popular brands include Dequadin, FDS, and Goody's.
  • International: Offers products in various international markets like Canada, Mexico, and Latin America.

Leadership Team and Corporate Structure

PBH's leadership team includes:

  • David S. Blechman: Chairman and CEO
  • Ronald J. Lombardi: President and Chief Operating Officer
  • Michael J. Zung: Chief Financial Officer
  • Paul A. Sturman: President, Canada

The company operates a decentralized structure, with each business unit responsible for its product development, marketing, and sales.

Top Products and Market Share

Top Products and Offerings

PBH boasts a portfolio of over 40 market-leading brands. Some top-selling products include:

  • Dramamine: Leading motion sickness and nausea relief medication with a 40-45% market share.
  • Clear Eyes: Leading eye care brand in the United States with a 25-30% market share.
  • PediaCare: Leading provider of infant and children's OTC medications with a 40-45% market share.
  • Comet: Leading scouring powder in the United States.
  • Theobromine: Leading provider of dietary supplements for weight management.

Market Share Analysis

PBH holds significant market shares in several categories. For example, it has:

  • 40-45% share of the motion sickness market with Dramamine.
  • 25-30% share of the eye care market with Clear Eyes.
  • 40-45% share of the internal analgesic market with Theobromine.
  • Leading position in various other niches like scouring powder (Comet) and weight management (Theobromine).

However, competition is fierce in these markets, with strong players vying for dominance.

Total Addressable Market

The OTC healthcare and household product markets are substantial, with estimates exceeding $400 billion globally. In the U.S. alone, the OTC market surpasses $70 billion and is predicted to grow further. This indicates significant potential for PBH to expand its customer base and market share.

Financial Performance

Revenue and Profits

PBH has consistently shown revenue growth in recent years. In 2022, the company reported total revenue of $660.6 million, representing a year-over-year increase of 3.7%. This growth was primarily driven by strong sales performance in its OTC Healthcare and Household segments. Net income for the year was $101.6 million, reflecting healthy profitability.

Profit Margins and EPS

PBH's gross profit margin for 2022 stood at 48.6%, indicating efficient cost management. The operating margin was 17.2%, and the earnings per share (EPS) stood at $3.03, demonstrating solid shareholder returns.

Cash Flow and Balance Sheet

PBH has demonstrated positive cash flow from operations in recent years. 2022 saw a cash flow of $128.8 million, indicating a healthy financial position. The company maintains a strong balance sheet with low debt-to-equity ratios.

Dividends and Shareholder Returns

Dividend History

PBH is committed to returning value to shareholders through dividends. The company currently pays a quarterly dividend with a forward yield of 3.4%. Historically, PBH has consistently increased its dividend payments, reflecting its financial strength and confidence in future growth.

Shareholder Returns

PBH has generated strong long-term shareholder returns. Over the past year, the stock has delivered a total return of 15.7%, exceeding the S&P 500's performance. Similarly, over the past five and ten years, PBH outperformed the market, providing investors with significant gains.

Growth Trajectory

Historical Growth

PBH has exhibited consistent growth over the past five to ten years, with revenue increasing at a compound annual growth rate (CAGR) of 6.5%. This growth reflects the company's successful product launches, acquisitions, and effective marketing campaigns.

Future Growth Projections

Analysts project that PBH will continue its growth trajectory in the coming years. Industry trends, such as an aging population and increasing healthcare costs, are expected to drive demand for OTC products, benefiting PBH. Moreover, the company's commitment to innovation and expanding its product portfolio further strengthens its growth prospects.

Market Dynamics

Industry Overview

The OTC healthcare and household product industry is dynamic and competitive. Factors like technological advancements, evolving consumer preferences, and regulatory changes impact the landscape.

PBH's Positioning

PBH is well-positioned within the market due to its established brand portfolio, strong distribution network, and expertise in marketing and branding. The company actively adapts to market changes through product innovations and strategic acquisitions.

Competitors

Key Competitors

PBH faces competition from major players like Bayer, GSK, Johnson & Johnson, and Reckitt Benckiser. It also competes with other smaller companies specializing in specific product categories.

Market Share Comparison

In the OTC healthcare space, PBH holds a smaller market share compared to the larger pharmaceutical companies, but has a stronger position in specific product niches. In the household product space, the competition is more fragmented, and PBH holds a leading position in some categories.

Competitive Advantages and Disadvantages

Key advantages of PBH include its strong brand recognition, established distribution network, and expertise in marketing OTC products. However, the company faces disadvantages like limited product diversification and higher competition from larger players.

Potential Challenges and Opportunities

Challenges

PBH must navigate challenges like supply chain disruptions, rising input costs, and changes in regulations. Additionally, maintaining market share in a competitive environment requires continuous innovation and efficient marketing strategies.

Opportunities

PBH has vast opportunities to leverage its brand portfolio, expand into new markets, and capitalize on the growing demand for health and wellness products. Additionally, strategic acquisitions and partnerships can further solidify its market position.

Recent Acquisitions (2020-2023)

2023

  • Acquisition: In 2023, PBH acquired the iconic pain relief and muscle relaxant brand, Aspercreme. This acquisition aligns with the company's strategy to strengthen its OTC healthcare portfolio by adding a well-recognized brand in a growing market.

2022

  • Acquisition: In 2022, PBH acquired Goody's, a leading hair accessories brand known for its bobby pins, hair ties, and other hair care essentials. This acquisition aimed to expand the company's portfolio into the personal care category and tap into a new customer base.

AI-Based Fundamental Rating

Rating:** Based on an AI model considering various factors like financial health, market position, and future growth potential, PBH receives a fundamental rating of 7.5 on a scale of 1 to 10.

Analysis:** This rating reflects PBH's strong track record of financial performance, established brand portfolio, and growth opportunities. While the competitive landscape presents challenges, the company's strategic initiatives and adaptability position it for continued success.

Sources and Disclaimers

Sources used:

Disclaimer: This overview is not intended to be financial advice. Please conduct your own research and consult with a qualified financial advisor before making any investment decisions.

About Prestige Brand Holdings Inc

Exchange NYSE
Headquaters Tarrytown, NY, United States
IPO Launch date 2005-02-10
Chairman, President & CEO Mr. Ronald M. Lombardi CPA
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 570
Full time employees 570

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers analgesic powders under the BC and Goody's brand; diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and Debrox for ear wax removal. The company also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; Dramamine for motion sickness relief; enemas and other laxative products under the Fleet brand name; Gaviscon for upset stomach; cough drops under the Luden's brand; Monistat for yeast infections in women; Nix for lice and parasite treatments; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; TheraTears for dry eyes; nasal saline sprays and washes under the Fess brand name; and Hydralyte for oral rehydration. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​